Abstract
Objective: Report our results with Florical in stabilizing hearing loss in patients with early otosclerosis. Method: A retrospective chart review was undertaken of patients with early otosclerosis treated with Florical. Using a paired t test, comparisons were made in amount of change between speech recognition threshold (SRT) and pure tone average (PTA) air-bone gap (ABG). A P-value of < .05 was considered statistically significant. Results: Eight patients with 10 affected ears were studied. Average age was 44.1 ± 14.2 years old. No statistically significant decline was detected at 3, 6, and 12 months in SRT ( P-value = 1.0, .68, .68, respectively) and PTA ABG ( P-value = .46, .61, and .39, respectively). Baseline average ABG was 10.5 ± 8.7 dB. Eight of the 10 ears experienced improvement of PTA ABG (mean = 6.6 ± 5.7 dB). One patient (1 ear) had complete closure of the PTA ABG. Mean follow-up was 5.7 months. No patients discontinued use of Florical because of adverse side effects. Only 2 patients (25%) reported dyspepsia. Conclusion: Our early experience demonstrates that Florical may prevent hearing deterioration and even reversal of early conductive hearing loss. It may be better tolerated than other sodium fluoride preparations, as calcium carbonate may help to alleviate the gastrointestinal side effects associated with sodium fluoride administration.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call